Incidence and clinical implication of trimethoprim/sulfamethoxazole susceptibility discrepancy between VITEK-2 and disc diffusion testing methods in Central Australia [0.03%]
中央澳大利亚VITEK-2和纸片扩散试验方法对甲氧苄氨嘧啶/磺胺甲基异噁唑的药敏不符情况及其临床意义
Georgia Cramp,William Naughton,James Mcleod et al.
Georgia Cramp et al.
Objectives: To investigate the incidence and clinical implications of the discrepancy of trimethoprim/sulfamethoxazole (TMP-SMX) susceptibility results produced by VITEK-2 and disc diffusion methods for Staphylococcus aur...
Current practices and opportunities in antibiotic allergy delabeling: a national cross-sectional survey [0.03%]
全国范围的横断面调查发现的当前抗生素过敏解除标签的实践和机会
Eva Groot,Lieke H Roest,Juul Aarts et al.
Eva Groot et al.
Paradoxical worsening on olorofim in patients undergoing treatment for invasive fungal diseases [0.03%]
侵袭性真菌病患者在接受奥罗罗非米治疗期间出现矛盾性加重
George R Thompson rd,Anke H W Bruns,Jannik Helweg-Larsen et al.
George R Thompson rd et al.
Objectives: Paradoxical reactions to appropriate antimicrobial therapy are seldom reported in systemic fungal diseases. Olorofim (formerly F901318) is an orally available first-in-class antifungal and exhibits in vitro ki...
How To: The Application and Analysis of Categorical Agreement in Antimicrobial Susceptibility Testing using EUCAST Breakpoints [0.03%]
如何应用和分析EUCAST折点在抗菌药物敏感性测试中的分类一致性
John Turnidge,Gunnar Kahlmeter,Christian G Giske et al.
John Turnidge et al.
Background: In 2019, the European Committee on Antimicrobial Susceptibility Testing (EUCAST) changed the definitions of susceptibility testing categories S, I and R. The most notable change was the definition of the I cat...
Non-invasive diagnosis of pulmonary tuberculosis using face mask sampling: A prospective study in adults [0.03%]
基于口罩采样的肺结核非侵入诊断方法：一项成人前瞻性研究
Dariusz Woelk,Lennard Meiwes,Nelly Ciobanu et al.
Dariusz Woelk et al.
Objectives: Sputum-based diagnostic methods for pulmonary tuberculosis (TB), including culture and nucleic acid amplification tests, provide high sensitivity and specificity. However, these methods rely on the patients' a...
Evaluation of rectal swab compared to bulk stool sampling for detection of Cryptosporidium infection by light-emitting diode auramine-phenol microscopy in young children with diarrhoea [0.03%]
评估LED Auramine-P酸性品红染色显微镜检测腹泻儿童粪便和肛拭子标本中隐孢子虫感染的效果
Degu Abate,Lucy J Robertson,Berhanu Seyoum et al.
Degu Abate et al.
Objectives: Traditionally, the detection of intestinal parasites, including Cryptosporidium, has relied on microscopic examination of bulk stool samples. However, obtaining bulk stool samples requires waiting time, collec...
Re: 'Association between multidrug-resistant organism status and quality of end-of-life care in patients with advanced cancer referred to palliative care' by Kim et al [0.03%]
关于Kim等人论文“难辨梭菌感染与晚期癌症转诊至姑息治疗的患者的生命质量及濒死质量之间关系”的评论
Bhumesh Tyagi,Leelabati Toppo,Aishwarya Biradar
Bhumesh Tyagi
The future of invasive mould infections - challenges, novelties and changing paradigms [0.03%]
侵袭性真菌感染的未来——挑战、创新和观念更新
Jannik Stemler,Oliver A Cornely
Jannik Stemler
Tetracycline hydrochloride susceptibility for prediction of antimicrobial susceptibility to doxycycline, minocycline, and tigecycline against Gram-negative and Gram-positive bacteria [0.03%]
四环素盐酸盐的敏感性预测对革兰氏阴性和革兰氏阳性细菌的多西环素、米诺环素和替加环素的抗菌敏感性
Maroun M Sfeir
Maroun M Sfeir
Objectives: Antimicrobial susceptibility testing of multiple antimicrobial agents within the same class remains challenging for clinical microbiology laboratories. The evidence behind the use of tetracycline hydrochloride...
Efficacy, safety, pharmacokinetics, immunogenicity, and serum neutralizing activity of AZD7442 (tixagevimab-cilgavimab) in hospitalized COVID-19 patients: long-term results from the DisCoVeRy trial [0.03%]
AZD7442（替沙西马-西加利维马）在住院COVID-19患者中的疗效、安全性、药代动力学、免疫原性和血清中和活性：DisCoVeRy试验的长期结果
Clément R Massonnaud,Nathan Peiffer-Smadja,Pascal Poignard et al.
Clément R Massonnaud et al.
Objectives: To report long-term clinical efficacy, safety, pharmacokinetics, immunogenicity and seroneutralization results of AZD7442 (monoclonal antibodies tixagevimab-cilgavimab) in hospitalized COVID-19 patients. ...